Figure 6

Sorafenib and lapatinib treatment inhibits tumor growth in mice inoculated with human colorectal tumor xenografts. Male NOD SCID mice bearing tumors derived from human HT-29 colorectal cancer cells were fed daily with 80 mg/kg of sorafenib and 60 mg/kg of lapatinib (a, c) or 1 mg/kg of lapatinib as the control (b, d) for 10 days. The tumor size (a, b) and body weights (c, d) of each mouse were measured every 2 days as indicated.